Patents by Inventor David Castillejos
David Castillejos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8691874Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.Type: GrantFiled: April 12, 2012Date of Patent: April 8, 2014Assignee: Kato Pharmaceuticals, Inc.Inventors: Vicken H. Karageozian, David Castillejos, John Park
-
Patent number: 8267995Abstract: An intra scleral implant and method of implantation for use in the treatment of intraocular pressure and presbyopia. The implant features a body portion and protrusions from the body portion to anchor the device in a cavity formed in the scleral wall of the eye. Optionally a drug delivery function is provided to allow long term communication of drugs to tissue surrounding the implant.Type: GrantFiled: August 2, 2002Date of Patent: September 18, 2012Inventor: David Castillejos
-
Publication number: 20120196937Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.Type: ApplicationFiled: April 12, 2012Publication date: August 2, 2012Applicant: KATO PHARMACEUTICALS, INC.Inventors: Vicken H. Karageozian, David Castillejos, John Park
-
Patent number: 8157759Abstract: An implantable drain for the anterior chamber of the eye for venting fluid therefrom to relieve pressure. The device features a serpentine draining conduit having an aggregate length much longer than a liner conduit. The conduit is engaged within the sclera in a pocket formed under a scleral flap. The conduits may be interchanged with a shunt or other component communicating into the anterior chamber.Type: GrantFiled: May 18, 2009Date of Patent: April 17, 2012Assignee: Ocumatrix, Inc.Inventor: David Castillejos
-
Patent number: 7981096Abstract: An method and a device for implant into the eye of a patient configured in size to frictionally engage within a cup-like depression naturally occurring in the optic nerve of the eye. The implant has a reservoir for calculated disbursement of medicine to tissue surrounding it and in one mode is refillable and in another mode is formed of biodegradable material which is absorbed by the patient after use ceases.Type: GrantFiled: May 11, 2007Date of Patent: July 19, 2011Inventor: David Castillejos
-
Patent number: 7977385Abstract: Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g.Type: GrantFiled: March 14, 2003Date of Patent: July 12, 2011Assignee: Numoda Biotechnologies, Inc.Inventors: Vicken H. Karageozian, David Castillejos, John Park, Gabriel Arthuro Carpio Aragon, Jose Luis Gutierres Floress
-
Publication number: 20090287136Abstract: An implantable drain for the anterior chamber of the eye for venting fluid therefrom to relieve pressure. The device features a serpentine draining conduit having an aggregate length much longer than a liner conduit. The conduit is engaged within the sclera in a pocket formed under a scleral flap. The conduits may be interchanged with a shunt or other component communicating into the anterior chamber.Type: ApplicationFiled: May 18, 2009Publication date: November 19, 2009Inventor: David Castillejos
-
Publication number: 20070265599Abstract: An method and a device for implant into the eye of a patient configured in size to frictionally engage within a cup-like depression naturally occurring in the optic nerve of the eye. The implant has a reservoir for calculated disbursement of medicine to tissue surrounding it and in one mode is refillable and in another mode is formed of biodegradable material which is absorbed by the patient after use ceases.Type: ApplicationFiled: May 11, 2007Publication date: November 15, 2007Inventor: David Castillejos
-
Publication number: 20070219632Abstract: An apparatus and method for treating presbyopia and lowering intraocular pressure employing an intra-scleral implant into an elongated cavity oriented in the radial direction of the eye. The implant has a planar portion with a longitudinal axis running therethrough and a pair of extension portions extending a distance away from said planar portion and said longitudinal axis. The implant is implanted in an incision in four quadrants of the sclera. The incisions are shaped similar to the implants. The projecting extensions into side projections of the incisions, provide an anchor to maintain the implant in the sclera.Type: ApplicationFiled: May 11, 2007Publication date: September 20, 2007Inventor: David Castillejos
-
Publication number: 20070105950Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.Type: ApplicationFiled: October 23, 2006Publication date: May 10, 2007Applicant: Vitreo-Retinal Technologies, Inc.Inventors: Vicken Karageozian, David Castillejos, John Park
-
Publication number: 20070027537Abstract: An apparatus and method for treating presbyopia and lowering intraocular pressure employing an intra-scleral implant into an elongated cavity oriented in the radial direction of the eye. The implant has a planar portion with a longitudinal axis running therethrough and a pair of extension portions extending a distance away from said planar portion and said longitudinal axis. The implant is implanted in an incision in four quadrants of the sclera. The incisions are shaped similar to the implants. The projecting extensions into side projections of the incisions, provide an anchor to maintain the implant in the sclera.Type: ApplicationFiled: September 27, 2006Publication date: February 1, 2007Inventor: David Castillejos
-
Patent number: 7008960Abstract: Methods and preparatons for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.Type: GrantFiled: August 9, 2002Date of Patent: March 7, 2006Assignee: Vitreo-Retinal Technologies, Inc.Inventor: David Castillejos
-
Publication number: 20050137124Abstract: Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.Type: ApplicationFiled: February 17, 2005Publication date: June 23, 2005Inventor: David Castillejos
-
Publication number: 20040043082Abstract: Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g.Type: ApplicationFiled: March 14, 2003Publication date: March 4, 2004Applicant: Vitreo-Retinal Technologies, Inc.Inventors: Vicken H. Karageozian, David Castillejos, John Park, Gabriel Arthuro Carpio Aragon, Jose Luis Gutierres Floress
-
Publication number: 20040024453Abstract: An intra scleral implant and method of implantation for use in the treatment of intraocular pressure and presbyopia. The implant features a body portion and protrusions from the body portion to anchor the device in a cavity formed in the scleral wall of the eye. Optionally a drug delivery function is provided to allow long term communication of drugs to tissue surrounding the implant.Type: ApplicationFiled: August 2, 2002Publication date: February 5, 2004Applicant: GLAUCOMA RESEARCH TECHNOLOGIES, INC.Inventor: David Castillejos
-
Publication number: 20030199574Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.Type: ApplicationFiled: February 13, 2003Publication date: October 23, 2003Applicant: Vitreo-Retinal Technologies, Inc.Inventors: Vicken H. Karageozian, David Castillejos, John Park
-
Patent number: 6462071Abstract: Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.Type: GrantFiled: March 2, 2000Date of Patent: October 8, 2002Assignee: Vitreo-Retinal Technologies, Inc.Inventor: David Castillejos